Skip to main content

Moderna, Inc. company profile

  • MRNA · Nasdaq
  • Biotechnology
  • S&P 500
$223.37−3.45%Close 13 Nov 2026

About Moderna, Inc.

Moderna is a biotechnology company focused on mRNA medicines, developing vaccines and therapeutics built on its mRNA technology platform. Its three commercial products are Spikevax and mNEXSPIKE, COVID-19 vaccines, and mRESVIA, an RSV vaccine for adults. Its pipeline spans infectious disease vaccines, oncology therapeutics and rare disease therapeutics, including candidates for seasonal influenza, a flu and COVID combination, norovirus, cytomegalovirus and Epstein-Barr virus. The company's products are sold to customers in multiple countries, and it operates a global manufacturing network with facilities in the United States, the UK, Canada and Australia. In 2025, its total revenue was $1.9 billion, largely from COVID vaccine sales.

A summary of the business section of the company's latest annual report, filed 20 Feb 2026.

Company facts

TickerMRNA · Nasdaq
SectorBiotechnology
IndustryBiotechnology
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK1682852
Latest annual report10-K, filed 20 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Stéphane BancelChief Executive Officer and Director30.7M · 7.6%—
Noubar B. Afeyan, Ph.D.Chairman7.1M · 1.8%Option exercise, 21 May 2026
Stephen Hoge, M.D.President5.2M · 1.3%Option exercise, 15 Oct 2026
Paul SaganDirector653K · < 1%Open-market purchase, 3 Mar 2025
Shannon Thyme KlingerChief Legal Officer180K · < 1%Shares withheld for tax, 4 Sep 2026
James MockChief Financial Officer170K · < 1%Option exercise, 5 Oct 2026
François Nader, M.D.Director115K · < 1%—
Sandra Horning, M.D.Director74.0K · < 1%Option exercise, 30 Apr 2026
Elizabeth TallettDirector70.9K · < 1%Option exercise, 30 Apr 2026
Elizabeth Nabel, M.D.Director38.9K · < 1%Option exercise, 30 Apr 2026
David RubensteinDirector31.5K · < 1%Option exercise, 30 Apr 2026
Abbas HussainDirector30.9K · < 1%Sale under a 10b5-1 plan, 1 May 2026
Bancel StephaneChief Executive Officer · Director—Option exercise, 6 Aug 2026
Nader FrancoisDirector—Option exercise, 30 Apr 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

MRNA in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.